How to Get Rezdiffra (Resmetirom) in Iowa

What Is Rezdiffra and Why Does It Matter for Iowa Patients?

Rezdiffra (resmetirom) is the first FDA-approved medication specifically indicated for metabolic dysfunction-associated steatohepatitis, or MASH, in adults with moderate to advanced liver fibrosis. The FDA granted accelerated approval in March 2024 based on surrogate endpoints of NASH resolution and fibrosis improvement. Before this approval, no pharmacotherapy carried an FDA indication for MASH, leaving Iowa's estimated 60,000-plus adults with the condition without a targeted drug option [1].

Resmetirom works as a liver-directed thyroid hormone receptor-beta (THR-β) agonist. It selectively activates THR-β in hepatocytes, reducing hepatic fat accumulation and fibrosis progression without the cardiovascular side effects associated with systemic thyroid hormone activation [2]. In the MAESTRO-NASH trial (N=966), 25.9% of patients on resmetirom 80 mg and 29.9% on 100 mg achieved NASH resolution with no worsening of fibrosis at 52 weeks, compared to 9.7% on placebo [2]. Fibrosis improvement by at least one stage occurred in 24.2% (80 mg) and 25.9% (100 mg) versus 14.2% on placebo.

These numbers changed the treatment algorithm for hepatologists across the Midwest. As Dr. Stephen Harrison, principal investigator of the MAESTRO-NASH trial, stated: "Resmetirom represents a mechanistically distinct approach that addresses the underlying metabolic drivers of MASH rather than just managing downstream complications" [2].

Iowa Prescribing Rules: Who Can Write the Prescription?

Any Iowa-licensed MD or DO can prescribe Rezdiffra. So can advanced registered nurse practitioners (ARNPs) and physician assistants operating under Iowa's collaborative practice frameworks. Iowa does not restrict resmetirom to hepatologists or gastroenterologists, though the clinical workup typically requires subspecialty-level interpretation.

The Iowa Board of Medicine allows prescribing via telehealth under Iowa Code Chapter 148 provided the clinician holds an active Iowa license and establishes a proper provider-patient relationship. This means an Iowa resident does not need an in-person visit to start Rezdiffra. A synchronous video consultation with a licensed prescriber satisfies the state requirement.

Primary care physicians who identify MASH through elevated ALT, imaging findings, or a FIB-4 score above 1.3 can initiate the referral process. The American Association for the Study of Liver Diseases (AASLD) recommends that prescribing decisions incorporate liver biopsy or validated noninvasive testing (such as FibroScan or the Enhanced Liver Fibrosis panel) to confirm fibrosis stage before starting therapy [3].

Required Labs Before Starting Rezdiffra in Iowa

Pretreatment laboratory evaluation is mandatory. It is not optional. The FDA label specifies thyroid function testing before initiation because resmetirom acts on thyroid hormone pathways, and patients with uncontrolled thyroid disease were excluded from the key trials [1].

The minimum lab panel includes:

• TSH and free T4: must be within normal limits. Patients with TSH outside 0.5 to 5.0 mIU/L require endocrine evaluation before starting resmetirom.
• Comprehensive metabolic panel (CMP): baseline hepatic transaminases (ALT, AST), bilirubin, albumin, and renal function.
• Complete blood count (CBC): to rule out cytopenias that could indicate advanced cirrhosis (Child-Pugh B or C), which is a contraindication.
• Lipid panel: resmetirom significantly lowers LDL cholesterol. In MAESTRO-NASH, LDL dropped by 13.6% at 80 mg and 16.3% at 100 mg versus placebo [2]. Patients on statins may need dose reassessment.
• FIB-4 score or FibroScan: to confirm fibrosis stage F1B through F3. Patients with compensated cirrhosis (F4) were not included in the trial population for the accelerated approval indication [1].

Iowa laboratories participating in major reference networks (LabCorp, Quest, and UnityPoint Health system labs) can process all required panels. Results are typically available within 48 to 72 hours.

Telehealth Access: Getting Rezdiffra Without Leaving Home

Iowa's telehealth regulations make remote prescribing straightforward. A board-certified hepatologist or gastroenterologist licensed in Iowa can evaluate a patient by video, review uploaded labs and imaging, confirm the MASH diagnosis and fibrosis stage, and transmit an electronic prescription to any Iowa pharmacy.

Three practical steps for Iowa telehealth patients:

1. Obtain labs locally. Visit any Iowa lab facility for the panels listed above. Upload results to your telehealth provider's portal.
2. Complete a synchronous video visit. Iowa requires real-time audiovisual interaction for new prescriptions. Asynchronous (store-and-forward) alone is not sufficient for initial prescribing.
3. Receive the e-prescription. The provider sends the Rezdiffra prescription electronically to a specialty pharmacy that stocks the medication.

Turnaround from first telehealth appointment to medication in hand typically runs 7 to 21 days when prior authorization is required. Without prior authorization (cash-pay patients), specialty pharmacies can often ship within 3 to 5 business days.

Pharmacy Options in Iowa: Retail, Specialty, and 503A

Rezdiffra is classified as a specialty medication by most payers. That classification means it is not stocked at standard retail pharmacies like Hy-Vee, Walgreens, or CVS locations in Iowa. Patients will typically fill prescriptions through one of three channels:

Specialty pharmacies. National specialty pharmacies (Accredo, CVS Specialty, OptumRx Specialty) ship directly to Iowa addresses. Madrigal Pharmaceuticals has designated a limited specialty pharmacy network for Rezdiffra distribution. Your prescriber's office or insurance plan will identify the in-network specialty pharmacy.

503A compounding pharmacies. Iowa permits licensed 503A compounding pharmacies to prepare and dispense medications based on individual patient prescriptions. A 503A pharmacy could compound resmetirom if it sources the active ingredient from an FDA-registered supplier. This route is less common for Rezdiffra given its availability as a manufactured product, but it exists as a legal option in Iowa for patients who need dose customization.

503B outsourcing facilities. These facilities operate under federal FDA oversight and can ship to Iowa providers and pharmacies without patient-specific prescriptions. They serve as a bulk supply channel for clinics.

The Iowa Board of Pharmacy oversees all in-state dispensing. Patients receiving shipped medications from out-of-state specialty pharmacies should confirm the pharmacy holds a nonresident Iowa license.

Insurance and Prior Authorization in Iowa

This is where most Iowa patients encounter friction. Coverage varies dramatically by payer.

Iowa Medicaid (Iowa Total Care, Amerigroup Iowa): Rezdiffra is not covered as of May 2026. Patients on Iowa Medicaid must pursue manufacturer assistance programs or appeal for medical exceptions. The Iowa Department of Health and Human Services has not added resmetirom to its preferred drug list.

Commercial insurance: Most commercial plans (Wellmark Blue Cross Blue Shield, UnitedHealthcare, Aetna) require prior authorization. The standard documentation package includes:

• Confirmed MASH diagnosis with histologic or noninvasive evidence
• Fibrosis staging showing F1B, F2, or F3
• Documentation that lifestyle modifications (diet, exercise, weight management) were attempted
• Baseline thyroid function within normal range
• Prescriber specialty or consultation note from hepatology/gastroenterology

Denial rates on initial submission run approximately 30% to 40% for resmetirom across commercial plans nationally, based on early post-launch data [4]. Most denials cite insufficient documentation rather than outright formulary exclusion. A peer-to-peer review between the prescribing physician and the plan's medical director often resolves the authorization.

Medicare Part D: Coverage decisions vary by plan. Patients enrolled in Medicare Advantage plans in Iowa (Wellmark Medicare, UnitedHealthcare AARP) should check formulary status directly. The Medicare Plan Finder tool allows formulary searches by drug name.

Madrigal Patient Support and Copay Assistance

Madrigal Pharmaceuticals operates the Rezdiffra Complete program for patients prescribed resmetirom. The program offers:

• Copay assistance for commercially insured patients, reducing out-of-pocket costs to as low as $0 per fill for eligible individuals. The program caps annual assistance at a set dollar amount.
• Free drug program for uninsured or underinsured patients who meet income criteria (typically below 400% of the federal poverty level).
• Prior authorization support through dedicated case managers who assist prescribers with documentation assembly and appeals.

Iowa patients can enroll by calling the number on the Rezdiffra prescribing information or through their prescriber's office. Enrollment typically takes one to two business days.

Timeline: How Long Until You Receive Rezdiffra in Iowa?

Expect the following approximate timeline from initial decision to first dose:

| Step | Duration | |---|---| | Lab work and results | 2 to 5 days | | Telehealth or in-person evaluation | 1 to 7 days (scheduling dependent) | | Prior authorization submission | 1 to 3 days | | Payer decision | 5 to 15 business days | | Specialty pharmacy processing and shipping | 3 to 5 business days | | Total estimated range | 12 to 35 days |

Patients paying cash or using manufacturer free drug programs bypass the prior authorization window, which can shorten the total to under two weeks. The step most likely to cause delays is payer review, especially if a peer-to-peer call is needed.

Clinical Monitoring After Starting Rezdiffra in Iowa

Once on therapy, Iowa patients need ongoing follow-up. The FDA label and clinical practice patterns call for:

• Thyroid function (TSH, free T4) at 4 to 8 weeks after initiation, then every 6 to 12 months. In MAESTRO-NASH, 1 in 200 patients experienced TSH elevation requiring dose adjustment [2].
• Hepatic panel (ALT, AST, bilirubin) at 12 weeks, then periodically. A small percentage of patients show transient ALT elevations within the first three months that typically self-resolve.
• Lipid panel at 12 weeks. The LDL-lowering effect of resmetirom may require statin dose reduction in patients already at LDL goal.
• Liver fibrosis assessment at 12 to 24 months. Noninvasive markers (FibroScan, ELF score, or FIB-4) can track fibrosis trajectory without repeat biopsy. The AASLD guidance on noninvasive assessment supports serial elastography for monitoring treatment response [3].

According to the AASLD's 2023 practice guidance: "Serial noninvasive tests should be used to monitor disease trajectory in patients on pharmacotherapy for MASH, with biopsy reserved for cases where noninvasive results are discordant or clinical status changes unexpectedly" [3].

Iowa's academic hepatology programs at the University of Iowa Hospitals and Clinics in Iowa City offer FibroScan and comprehensive MASH management. Community gastroenterology practices across Des Moines, Cedar Rapids, and Davenport also provide follow-up monitoring.

Transferring a Rezdiffra Prescription to Iowa

Patients relocating to Iowa from another state can transfer an existing Rezdiffra prescription. Iowa accepts prescription transfers from all 50 states under Iowa Administrative Code 657, Chapter 8. The receiving Iowa pharmacy contacts the originating pharmacy to verify and transfer the prescription record.

Two practical notes on transfers. First, the new Iowa pharmacy must be part of the specialty pharmacy network designated by the patient's insurance plan. A prescription transferred to an out-of-network pharmacy will trigger a coverage denial. Second, prior authorization from the previous state does not automatically carry over. The Iowa-based prescriber (or the patient's original prescriber, if still licensed in Iowa) may need to submit a new prior authorization to the patient's updated insurance plan.

For patients switching insurance during a move to Iowa, Madrigal's patient support program can bridge the gap with temporary free drug supply while new authorization processes.

Safety Considerations Specific to Iowa's Population

Iowa ranks among the top 15 states for adult obesity prevalence, with 37.4% of adults classified as obese according to CDC Behavioral Risk Factor Surveillance System data [5]. This epidemiologic profile means a substantial pool of Iowa residents may meet criteria for MASH screening. The American Gastroenterological Association's MASH clinical care pathway recommends screening adults with type 2 diabetes or obesity plus one additional metabolic risk factor using FIB-4 as the initial step [6].

Resmetirom's safety profile in MAESTRO-NASH showed the most common adverse events were diarrhea (26.5% at 100 mg vs. 16.5% placebo) and nausea (22.1% at 100 mg vs. 13.5% placebo) [2]. These GI effects were generally mild, peaked in the first four weeks, and led to discontinuation in fewer than 3% of patients. Serious adverse events occurred at similar rates across resmetirom and placebo arms.

Patients with decompensated cirrhosis (Child-Pugh B or C) should not take resmetirom. The drug has not been studied in this population, and the FDA label carries a specific limitation against use in advanced liver disease beyond compensated F4 [1].